SCHEMBL31076218

SCHEMBL31076218

Cc1ccc(S(=O)(=O)Oc2cc(Br)ccc2N)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.51
MAPT P10636 4/20 0.47
KMT2A Q03164 6/20 0.43
MEN1 O00255 5/20 0.43
GAA P10253 3/20 0.43
ESR1 P03372 1/20 0.43
ESR2 Q92731 1/20 0.43
CYP2C19 P33261 2/20 0.43
LMNA P02545 3/20 0.42
MAPK1 P28482 1/20 0.42
GFER P55789 1/20 0.41
METAP2 P50579 1/20 0.41
ALDH1A1 P00352 4/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PKM P14618 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
P2RY12 Q9H244 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15442143 0.87 CYP1A2 (0.56) CYP1A2MAPTKMT2AMEN1GAA
SCHEMBL2074713 0.82 GFER (0.60) MAPTKMT2AMEN1GAALMNA
SCHEMBL17595116 0.82 KMT2A (0.56) CYP1A2MAPTKMT2AMEN1GAA
SCHEMBL15442501 0.81 KMT2A (0.44) CYP1A2MAPTKMT2AMEN1GAA
SCHEMBL15442934 0.81 ALDH1A1 (0.51) CYP1A2MAPTKMT2AMEN1GAA
SCHEMBL3690641 0.79 KMT2A (0.54) CYP1A2MAPTKMT2AMEN1GAA
SCHEMBL27714863 0.79 KMT2A (0.44) CYP1A2MAPTKMT2AMEN1GAA
SCHEMBL27735609 0.79 KMT2A (0.50) CYP1A2MAPTKMT2AMEN1GAA
SCHEMBL31076201 0.78 CYP1A2 (0.45) CYP1A2MAPTKMT2AMEN1GAA
SCHEMBL15443118 0.78 CYP1A2 (0.56) CYP1A2MAPTKMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688791-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2026-02-11 EP disclosed
US-20250376482-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2025-12-11 US disclosed
US-12247036-B2 Tricyclic compounds for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2025-03-11 US disclosed
US-20240417410-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2024-12-19 US disclosed
EP-4469164-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2024-12-04 EP disclosed
WO-2024208934-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2024-10-10 WO disclosed
WO-2024169914-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2024-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376482-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B CYP1A2 231/4885MAPT 3834/4885KMT2A 1020/4885
US-20240417410-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B CYP1A2 231/4885MAPT 3834/4885KMT2A 1020/4885
US-12247036-B2 Tricyclic compounds for the treatment of cancer H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B CYP1A2 231/4885MAPT 3834/4885KMT2A 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.